[1]
|
M. R. Middleton, et al., “Randomized Phase III Study of Temozolomide versus Dacarbazine in the Treatment of Patients with Advanced Metastatic Malignant Melanoma,” Journal of Clinical Oncology, Vol. 18, No. 1, 2000, pp. 158-166.
|
[2]
|
C. G. Willett, et al., “Direct Evidence That the VEGF-Specific Antibody Bevacizumab Has Antivascular Effects in Human Rectal Cancer,” Nature Medicine, Vol. 10, No. 2, 2004, pp. 145-147. doi:10.1038/nm988
|
[3]
|
K. A. Varker, et al., “A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma,” Annals of Surgical Oncology, Vol. 14, No. 8, 2007, pp. 2367-2376.
doi:10.1245/s10434-007-9389-5
|
[4]
|
D. G. Perez, et al., “Phase 2 Trial of Carboplatin, Weekly Paclitaxel, and Biweekly Bevacizumab in Patients with Unresectable Stage IV Melanoma: A North Central Cancer Treatment Group Study, N047A,” Cancer, Vol. 115, No. 1, 2009, pp. 119-127. doi:10.1002/cncr.23987
|
[5]
|
S. J. O’Day, J. A. Sosman, et al., “BEAM: A Randomised Phase II Study Evaluating the Activity of Bevacizumab in Combination with Carboplatin plus Paclitaxel in Patients with Previously Untreated Advanced Melanoma., in EC-CO-ESMO European Cancer Congress,” Cancer, Vol. 7, No. 3, 2009, p. 23.
|
[6]
|
M. Del Vecchio, et al., “Bevacizumab plus Fotemustine as First-Line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors,” Clinical Cancer Research, Vol. 16, No. 23, 2010, pp. 5862-5872.
doi:10.1158/1078-0432.CCR-10-2363
|
[7]
|
M. F. Avril, et al., “Fotemustine Compared with Dacarbazine in Patients with disseminated malignant melanoma: A Phase III Study,” Journal of Clinical Oncology, Vol. 22, No. 6, 2004, pp. 1118-1125.
doi:10.1200/JCO.2004.04.165
|
[8]
|
K. A. Varker, et al., “A Randomized Phase 2 Trial of bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma,” Annals of Surgical Oncology, Vol. 14, No. 8, 2007, pp. 2367-2376.
doi:10.1245/s10434-007-9389-5
|
[9]
|
R. Von Moos, et al., “First-Line Temozolomide Combined with Bevacizumab in Metastatic Melanoma: A Multicentre Phase II Trial (SAKK 50/07),” Annals of Oncology, Vol. 23, No. 2, 2011, pp. 531-536.
|
[10]
|
S. S. Agarwala, J. M. Kirkwood, M. Gore, B. Dreno, N. Thatcher, B. Czarnetski, M. Atkins, A. Buzaid, D. Skarlos and E. M. Rankin, “Temozolomide for the Treatment of Brain Metastases Associated with Metastatic Melanoma: A Phase II Study,” Journal of Clinical Oncology, Vol. 22, No. 11, 2004, pp. 2101-2107.
doi:10.1200/JCO.2004.11.044
|
[11]
|
R. O. Pritchard-Jones, et al., “Expression of VEGFxxxb, the Inhibitory Isoforms of VEGF, in Malignant Melanoma,” British Journal of Cancer, Vol. 97, No. 2, 2007, pp. 223-230. doi:10.1038/sj.bjc.6603839
|
[12]
|
A. H. R. Varey, et al., “VEGF165b, an Antiangiogenic VEGF-A Isoform, Binds and Inhibits Bevacizumab Treatment in Experimental Colorectal Carcinoma: Balance of Pro- and Antiangiogenic VEGF-A Isoforms Has Implications for Therapy,” British Journal of Cancer, Vol. 98, No. 8, 2008, pp. 1366-1379.
doi:10.1038/sj.bjc.6604308
|
[13]
|
S. M. Wilhelm, C. Carter, L. Tang, et al., “BAY43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis,” Cancer Research, Vol. 64, 2004, pp. 7099-7109. doi:10.1158/0008-5472.CAN-04-1443
|
[14]
|
T. Eisen, et al., “Sorafenib in Advanced Melanoma: A Phase II Randomised Discontinuation Trial Analysis,” British Journal of Cancer, Vol. 95, No. 5, 2006, pp. 581-586. doi:10.1038/sj.bjc.6603291
|
[15]
|
A. Hauschild, et al., “Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination with Carboplatin and Paclitaxel as Second-Line Treatment in Patients with Unresectable Stage III or Stage IV Melanoma,” Journal of Clinical Oncology, Vol. 27, No. 17, 2009, pp. 2823-2830. doi:10.1200/JCO.2007.15.7636
|
[16]
|
P. A. Ott, et al., “A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates to Surgical Approach to Primary Cutaneous Melanoma Mucosal Melanomas: A Case-Based Review of the Literature A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma,” PLoS One, Vol. 5, No. 12, 2010, p. 15588.
doi:10.1371/journal.pone.0015588
|
[17]
|
F. Egberts, et al., “Sorafenib and Pegylated Interferon-{alpha}2b in Advanced Metastatic Melanoma: A Multicenter Phase II DeCOG Trial,” Annals of Oncology, Vol. 10, 2011, p. 10.
|
[18]
|
R. Amaravadi, D. F. Mc Dermott, et al., “Updated Results of a Randomised Phase II Study Comparing Two Schedules of Temozolamide in Combination with Sorafenib in Patients with Advanced Melanoma,” Journal of Clinical Oncology, Vol. 25, No. 18s, 2007, p. 8527.
|
[19]
|
B. Escudier, T. Eisen, W. M. Stadier, et al., “Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial,” Journal of Clinical Oncology, Vol. 27, 2009, pp. 3312-3318.
doi:10.1200/JCO.2008.19.5511
|
[20]
|
J. P. Fruehauf, J. Lutzky and D. F. McDermott, “Axitinib (AG-013736) in Patients with Metastatic Melanoma: A Phase II Study,” Journal of Clinical Oncology, Vol. 26, 2008, p. 9006.
|
[21]
|
E. G. Troost, et al., “18F-FLT PET Does not Discriminate between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients,” Journal of Nuclear Medicine, Vol. 48, No. 5, 2007, pp. 726-735.
doi:10.2967/jnumed.106.037473
|
[22]
|
A. Abramsson, P. Lindblom and C. Betsholtz, “Endothelial and Nonendothelial Sources of PDGF-B Regulate Pericyte Recruitment and Influence Vascular Pattern Formation in Tumors,” Journal of Clinical Investigation, Vol. 112, No. 8, 2003, pp. 1142-1151.
|
[23]
|
J. C. Becker, E. B. Brocker, D. Schadendorf and S. Ugurel, “Imatinib in Melanoma: A Selective Treatment Option Based on KIT Mutation Status?” Journal of Clinical Oncology, Vol. 25, No. 7, 2007, p. 9.
|
[24]
|
K. T. Flaherty, et al., “Inhibition of Mutated, Activated BRAF in Metastatic Melanoma,” The New England Journal of Medicine, Vol. 363, No. 9, 2010, pp. 809-819. doi:10.1056/NEJMoa1002011
|
[25]
|
F. S. Hodi, et al., “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma,” The New England Journal of Medicine, Vol. 363, No. 8, 2010, pp. 711-723. doi:10.1056/NEJMoa1003466
|
[26]
|
T. Eisen, et al., “Results of a Multicenter, Randomized, Double-Blind Phase 2/3 Study of Lenalidomide in the Treatment of Pretreated Relapsed or Refractory Metastatic Malignant Melanoma,” Cancer, Vol. 116, No. 1, 2010, pp. 146-154.
|
[27]
|
D. Wolchok, I. N. Bondarenko, S. O’Day, J. S. Weber, C. Garbe, S. Francis, R. A. Ibrahim, A. Hoos, C. Robert, “Phase III Randomized Study of Ipilimumab (IPI) plus Dacarbazine (DTIC) versus DTIC Alone as First-Line Treatment in Patients with Unresectable Stage III or IV Melanoma,” Journal of Clinical Oncology, Vol. 29, 2011.
|
[28]
|
S. Kotapati, M. Ouwens, M. van Baardewijk, R. A. Ibrahim, S. Wagner, J. P. Jansen, “Overall Survival (OS) in the Management of Pretreated Patients with Unresectable Stage III/IV Melanoma: A systematic Literature Review and Meta-Analysis,” Journal of Clinical Oncology, Vol. 29, 2011.
|
[29]
|
S. Hodi, M. B. Atkins, D. F. McDermott, D. P. Lawrence, N. Ibrahim, X. Wu, J. Zhou, A. Giobbie-Hurder, G. Murphy, T. Hollman, E. Velazquez, S. Russell, P. Dipiro, J. T. Yap and A. D. Van Den Abbeele, “A Phase I Trial of Ipilimumab plus bevacizumab in patients with Unresectable Stage III or Stage IV Melanoma,” Journal of Clinical Oncology, Vol. 29, 2011.
|
[30]
|
H. Davies, et al., “Mutations of the BRAF Gene in Human Cancer,” Nature, Vol. 417, No. 6892, 2002, pp. 949-954. doi:10.1038/nature00766
|
[31]
|
Y. Mizukami, Y. Kohgo and D. C. Chung, “Hypoxia Inducible Factor-1 Independent Pathways in Tumor Angiogenesis,” Clinical Cancer Research, Vol. 13, No. 19, 2007, pp. 5670-5674.
doi:10.1158/1078-0432.CCR-07-0111
|
[32]
|
A. M. Menzies, M. D. Chatfield, M. S. Carlino, J. R. Howle, R. A. Scolyer, J. F. Thompson, R. F. Kefford and G. V. Long, “BRAF Mutation by Age-Decade and Body Mass Index in Metastatic Melanoma,” Journal of Clinical Oncology, Vol. 29, 2011.
|
[33]
|
W. H. Sharfman, D. P. Lawrence, K. T. Flaherty, R. K. Amaravadi, K. B. Kim, R. Dummer, S. Gobbi, I. Puzanov, J. A. Sosman, K. Dohoney, L. P. Lam, S. Kakar, Z. Tang, O. Krieter and M. B. Atkins, “Results from the First-in-Human (FIH) Phase I Study of the Oral RAF inhibitor RAF265 Administered Daily to Patients with Advanced Cutaneous Melanoma,” Journal of Clinical Oncology, Vol. 29, 2011.
|
[34]
|
K. T. Flaherty, H. Sosman, et al., “Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer,” Journal of Clinical Oncology, Vol. 27, No. 15S, 2009.
|
[35]
|
P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary , D. Schadendorf, A. Ribas, S. J. O’Day, J. A. Sosman, J. M. Kirkwood, A. M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R. J. Lee, K. T. Flaherty and A. G. McArthur, “Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation,” New England Journal of Medicine, Vol. 364, 2011, pp. 2507-2516.
doi:10.1056/NEJMoa1103782
|
[36]
|
A. Ribas, “An Open-Label, Multicentre Phase II Study of Vemurafenib (PLX4032, RG7204) in Previously Treated Patients with BRAFV600E Mutation Positive Metastatic Melanoma,” Journal of Clinical Oncology, Vol. 29, 2011.
|
[37]
|
P. B. Chapman, et al., “Phase III Randomized, Open-Label, Multicenter Trial (BRIM3) Comparing BRAF Inhibitor Vemurafenib with Dacarbazine in Patients with BRAFV600E-Mutated Melanoma,” Journal of Clinical Oncology, Vol. 29, 2011.
|
[38]
|
F. Su, H. Y. B. Higgins, K. D. Kolinsky, K. Packman, M. Kim, B. J. Lestini, G. Bollag and D. C. Heimbrook, “Molecular Mechanisms Underlying Disease Relapse on Treatment with Selective BRAF Inhibitor Vemurafenib (PLX4032),” Journal of Clinical Oncology, Vol. 29, 2011.
|
[39]
|
A. J. Eustace, S. K. A. Larkin, T. Mahgoub, D. Tryfonopoulos, L. O’Driscoll, M. Clynes, J. Crown and N. O’Donovan, “Identification of Predictive Biomarkers for Dasatinib Treatment Of Metastatic Melanoma,” Journal of Clinical Oncology, Vol. 29, 2011.
|
[40]
|
R. D. Rao, J. B. Allred, et al., “Phase II Trial of the mTOR Inhibitor Everolimus (RAD-001) in Metastatic Melanoma,” Journal of Clinical Oncology, Vol. 24, No. 18S, 2006.
|
[41]
|
I. Quirt, et al., “Phase II Study of Marimastat (BB-2516) in Malignant Melanoma: A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group,” Investigational New Drugs, Vol. 20, No. 4, 2002, pp. 431-437. doi:10.1023/A:1020625423524
|
[42]
|
L. H. Palavalli, et al., “Analysis of the Matrix Metalloproteinase Family Reveals that MMP8 Is Often Mutated in Melanoma,” Nature Genetics, Vol. 41, No. 5, 2009, pp. 518-520. doi:10.1038/ng.340
|
[43]
|
D. Brouty-Boye and B. R. Zetter, “Inhibition of Cell Motility by Interferon,” Science, Vol. 208, No. 4443, 1980, pp. 516-518. doi:10.1126/science.6154315
|
[44]
|
C. P. Dinney, et al., “Inhibition of Basic Fibroblast Growth Factor Expression, Angiogenesis, and Growth of Human Bladder Carcinoma in Mice by Systemic Interferon-Alpha Administration,” Cancer Research, Vol. 58, No. 4, 1998, pp. 808-814.
|
[45]
|
J. Drevs, et al., “Antiangiogenic Potency of Various Chemotherapeutic Drugs for Metronomic Chemotherapy,” Anticancer Research, Vol. 24, No. 3a, 2004, pp. 1759-1763.
|
[46]
|
S. J. O’Day, M. B. Atkins, P. Boasberg, H. J. Wang, J. A. Thompson, C. M. Anderson, R. Gonzalez, J. Lutzky, T. Amatruda, E. M. Hersh and J. S Weber, “Phase II Multicenter Trial of Maintenance Biotherapy after Induction Concurrent Biochemotherapy for Patients with Metastatic Melanoma,” Journal of Clinical Oncology, Vol. 27, No. 36, 2009, pp. 6207-6212. doi:10.1200/JCO.2008.20.3075
|
[47]
|
J. M. Pawelek and A. K. Chakraborty, “The Cancer Cell-Leukocyte Fusion Theory of Metastasis,” Advances in Cancer Research, Vol. 101, 2008, pp. 397-444.
doi:10.1016/S0065-230X(08)00410-7
|
[48]
|
J. Pawelek, et al., “Co-Opting Macrophage Traits in Cancer Progression: A Consequence of Tumor Cell Fusion?” Contrib Microbiol, 2006, Vol. 13, pp. 138-155.
doi:10.1159/000092970
|
[49]
|
J. M. Pawelek, “Tumour-Cell Fusion as a Source of Myeloid Traits in Cancer,” The Lancet Oncology, Vol. 6, No. 12, 2005, pp. 988-993.
doi:10.1016/S1470-2045(05)70466-6
|
[50]
|
J. M. Pawelek, “Viewing Malignant Melanoma Cells as Macrophage-Tumor Hybrids,” Cell Adhesion & Migration, Vol. 1, No. 1, 2007, pp. 2-6.
|
[51]
|
D. Hanahan and R. A. Weinberg, “The Hallmarks of Cancer,” Cell, Vol. 100, No. 1, 2000, pp. 57-70.
doi:10.1016/S0092-8674(00)81683-9
|
[52]
|
J. Chapman, et al., “Updated Overall Survival (OS) Results for BRIM-3, a Phase III Randomized, Open-Label, Multicenter Trial Comparing BRAF Inhibitor Vemurafenib (vem) with Dacarbazine (DTIC) in Previously Untreated Patients with BRAFV600E-Mutated Melanoma,” Journal of Clinical Oncology, Vol. 30, 2012.
doi:10.1056/NEJMoa1003466
|
[53]
|
F. S. Hodi, et al., “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma,” The New England Journal of Medicine, Vol. 363, No. 8, 2010, pp. 711-723.
doi:10.1056/NEJMoa1003466
|